Connected Drug Delivery Devices Market to Grow with a CAGR of 15.25% through 2030

Rising Prevalence of Chronic Diseases Requiring Long-Term Medication and Advancements in Digital Health Technologies and IoT Integration are expected to drive the Global Connected Drug Delivery Devices Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Connected Drug Delivery Devices Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Connected Drug Delivery Devices Market stood at USD 6.45 Billion in 2024 and is anticipated to grow with a CAGR of 15.25% in the forecast period, 2026-2030.

The global healthcare landscape is undergoing a structural shift toward decentralized, value-based care models that prioritize remote patient management, preventative health interventions, and cost-efficient service delivery. This transition has been significantly accelerated by the COVID-19 pandemic, which exposed systemic inefficiencies in traditional, facility-dependent healthcare models. In this evolving environment, connected drug delivery devices are emerging as critical enablers of home-based care. By facilitating self-administration of medications with integrated remote monitoring, these technologies allow clinicians to track adherence, detect early signs of non-compliance or adverse events, and intervene proactively without requiring frequent in-person interactions.

These devices not only improve patient convenience but also support broader healthcare system goals, such as reducing hospital readmissions, minimizing medication errors, and streamlining care delivery. For payers and providers, the ability to optimize resource allocation and extend clinical oversight beyond the hospital setting is increasingly recognized as a strategic advantage. As telehealth and digital therapeutics continue to gain regulatory and commercial traction, connected drug delivery systems are becoming foundational tools in next-generation, digitally integrated care pathways.

Pharmaceutical companies are responding to rising competitive pressure and evolving therapeutic pipelines particularly in the area of biologics and specialty medicines by embedding connected technologies into their drug delivery strategies. These solutions serve as a key differentiator by offering enhanced adherence support, real-time patient insights, and the ability to generate real-world evidence that supports value-based pricing models.

Strategic partnerships between pharma companies and digital health innovators are driving the co-development of smart injectors, AI-enabled monitoring platforms, and companion mobile applications, creating a broader ecosystem around each therapy. These platforms not only enrich patient experience but also assist manufacturers with regulatory compliance, post-market surveillance, and Risk Evaluation and Mitigation Strategies (REMS) for high-risk therapies. This growing alignment between connected drug delivery devices and pharmaceutical commercialization strategies is accelerating both investment and market adoption. As a result, smart delivery technologies are transitioning from optional enhancements to core components of patient-centric, digitally enabled therapeutic models.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Connected Drug Delivery Devices Market”

The Global Connected Drug Delivery Devices Market is segmented into product type, Route of Administration, application, regional distribution, and company.

Based on its product type, the standalone components and software segment has emerged as the predominant market leader, the primary advantages of standalone components and software is the ability to upgrade conventional drug delivery devices such as inhalers, insulin pens, autoinjectors, and syringes without redesigning or re-approving the entire product. This is highly cost-effective for both medical device manufacturers and pharmaceutical companies, especially those with established drug-device combinations. Smart caps for inhalers or insulin pens that monitor usage patterns and transmit data to a mobile app. Faster time-to-market and reduced regulatory complexity compared to fully embedded smart systems. Standalone solutions are modular and scalable, making them highly adaptable across various drug types, including Biologics and biosimilars, Chronic disease medications (e.g., diabetes, asthma, rheumatoid arthritis), High-cost specialty therapies. Software platforms in particular offer scalability across geographies, patient populations, and therapy areas, making them attractive for large-scale deployment.

Software platforms often paired with standalone sensors enable: Real-time adherence monitoring, Dose tracking, Symptom reporting, AI-powered intervention triggers. They integrate seamlessly with electronic health records (EHRs), payer portals, and remote patient monitoring systems, creating a unified ecosystem that supports value-based care models. Pharmaceutical firms and providers use this data to: Improve patient outcomes, Optimize dosing strategies, Generate real-world evidence, Enable performance-based contracting.

The Asia Pacific region is set to witness the fastest growth in the Global Connected Drug Delivery Devices Market, fueled by a combination of demographic shifts, healthcare infrastructure modernization, digital health adoption, and a rising chronic disease burden. While North America and Europe currently lead in market maturity, Asia Pacific is rapidly emerging as a high-potential growth engine driven by both public and private sector investment in smart healthcare solutions. The region is experiencing a sharp rise in non-communicable diseases (NCDs) such as diabetes, asthma, cardiovascular diseases, and cancer, which require long-term medication management. Countries like China, India, and Japan have large aging populations with a growing need for self-administered therapies that are safe, trackable, and easy to manage at home. This demographic trend is directly increasing demand for connected drug delivery systems that support medication adherence and remote monitoring.

Rapid digitization across healthcare systems in Asia Pacific is creating a favorable environment for the deployment of connected devices. Major economies are investing heavily in: 5G and cloud infrastructure, AI-powered health monitoring platforms, National digital health IDs and eHealth records. These advancements support seamless integration of connected drug delivery platforms with telemedicine and digital care ecosystems.

Major companies operating in Global Connected Drug Delivery Devices Market are:

• Teva Pharmaceutical Industries Ltd.
• Novo Nordisk A/S
• Phillips Medisize
• Medtronic Plc.
• Adherium Limited
• Tandem Diabetes Care, Inc.
• Biocorp Life Sciences Pvt. Ltd
• Resmed Corp
• Ypsomed AG
• AptarGroup, Inc

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Connected Drug Delivery Devices Market is positioned at the forefront of a paradigm shift in healthcare, where technology, personalized medicine, and patient engagement converge. As industry increasingly emphasizes real-world evidence, remote care models, and improved therapeutic outcomes, connected delivery systems are no longer viewed as optional enhancements but as essential components of modern treatment strategies. Backed by advancements in IoT, digital therapeutics, and AI-driven analytics, the market is poised for sustained growth across both developed and emerging economies. Stakeholders who invest in interoperable platforms, patient-centric design, and integrated digital ecosystems will be best positioned to capture value in this evolving, high-potential landscape.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Connected Drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type (Standalone Components & Software, Integrated Devices), By Route of Administration (Parenteral, Inhalational), By Application (Asthma, COPD, Diabetes Management, Others), By Region, & Competition, 2020-2030F”, has evaluated the future growth potential of Global Connected Drug Delivery Devices Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Connected Drug Delivery Devices Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]